139 related articles for article (PubMed ID: 34033809)
1. The Effect of Proton Pump Inhibitor Use on the Course of Kidney Function in Patients with Chronic Kidney Disease Stages G3a to G4.
Giusti S; Lin Y; Sogbetun F; Nakhoul N; Liu S; Shi L; Batuman V
Am J Med Sci; 2021 Nov; 362(5):453-461. PubMed ID: 34033809
[TBL] [Abstract][Full Text] [Related]
2. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury.
Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
Kidney Int; 2017 Jun; 91(6):1482-1494. PubMed ID: 28237709
[TBL] [Abstract][Full Text] [Related]
3. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study.
Hart E; Dunn TE; Feuerstein S; Jacobs DM
Pharmacotherapy; 2019 Apr; 39(4):443-453. PubMed ID: 30779194
[TBL] [Abstract][Full Text] [Related]
4. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
[TBL] [Abstract][Full Text] [Related]
5. Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: The CKD-REIN cohort study.
Liabeuf S; Lambert O; Metzger M; Hamroun A; Laville M; Laville SM; Frimat L; Pecoits-Filho R; Fouque D; Massy ZA; Jacquelinet C; Stengel B;
Br J Clin Pharmacol; 2021 Jul; 87(7):2967-2976. PubMed ID: 33368448
[TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitor use and progression to major adverse renal events: a competing risk analysis.
Grant CH; Gillis KA; Lees JS; Traynor JP; Mark PB; Stevens KI
QJM; 2019 Nov; 112(11):835-840. PubMed ID: 31251364
[TBL] [Abstract][Full Text] [Related]
7. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD.
Xie Y; Bowe B; Li T; Xian H; Balasubramanian S; Al-Aly Z
J Am Soc Nephrol; 2016 Oct; 27(10):3153-3163. PubMed ID: 27080976
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease.
Arora P; Gupta A; Golzy M; Patel N; Carter RL; Jalal K; Lohr JW
BMC Nephrol; 2016 Aug; 17(1):112. PubMed ID: 27487959
[TBL] [Abstract][Full Text] [Related]
9. Association between serum Na-Cl level and renal function decline in chronic kidney disease: results from the chronic kidney disease Japan cohort (CKD-JAC) study.
Maruta Y; Hasegawa T; Yamakoshi E; Nishiwaki H; Koiwa F; Imai E; Hishida A
Clin Exp Nephrol; 2019 Feb; 23(2):215-222. PubMed ID: 30168046
[TBL] [Abstract][Full Text] [Related]
10. Cancer patterns and association with mortality and renal outcomes in non-dialysis dependent chronic kidney disease: a matched cohort study.
Chinnadurai R; Flanagan E; Jayson GC; Kalra PA
BMC Nephrol; 2019 Oct; 20(1):380. PubMed ID: 31640599
[TBL] [Abstract][Full Text] [Related]
11. Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression.
Cholin L; Ashour T; Mehdi A; Taliercio JJ; Daou R; Arrigain S; Schold JD; Thomas G; Nally J; Nakhoul NL; Nakhoul GN
BMC Nephrol; 2021 Jul; 22(1):264. PubMed ID: 34266395
[TBL] [Abstract][Full Text] [Related]
12. Non-indicated initiation of proton pump inhibitor and risk of adverse outcomes in patients with underlying chronic kidney disease: a nationwide, retrospective, cohort study.
Kim SG; Cho JM; Han K; Joo KW; Lee S; Kim Y; Cho S; Huh H; Kim M; Kang E; Kim DK; Park S
BMJ Open; 2024 Jan; 14(1):e078032. PubMed ID: 38286693
[TBL] [Abstract][Full Text] [Related]
13. Metabolic acidosis is associated with increased risk of adverse kidney outcomes and mortality in patients with non-dialysis dependent chronic kidney disease: an observational cohort study.
Tangri N; Reaven NL; Funk SE; Ferguson TW; Collister D; Mathur V
BMC Nephrol; 2021 May; 22(1):185. PubMed ID: 34011303
[TBL] [Abstract][Full Text] [Related]
14. Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients.
Lee HJ; Lee H; Oh SH; Park J; Park S; Jeon JS; Noh H; Han DC; Kwon SH
PLoS One; 2018; 13(9):e0203878. PubMed ID: 30212538
[TBL] [Abstract][Full Text] [Related]
15. Duration and dosing of Proton Pump Inhibitors associated with high incidence of chronic kidney disease in population-based cohort.
Rodríguez-Poncelas A; Barceló MA; Saez M; Coll-de-Tuero G
PLoS One; 2018; 13(10):e0204231. PubMed ID: 30332411
[TBL] [Abstract][Full Text] [Related]
16. Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease.
Klatte DCF; Gasparini A; Xu H; de Deco P; Trevisan M; Johansson ALV; Wettermark B; Ärnlöv J; Janmaat CJ; Lindholm B; Dekker FW; Coresh J; Grams ME; Carrero JJ
Gastroenterology; 2017 Sep; 153(3):702-710. PubMed ID: 28583827
[TBL] [Abstract][Full Text] [Related]
17. Associations of urological malignancies with renal progression and mortality in advanced chronic kidney disease: a propensity-matched cohort study.
Chinnadurai R; Clarke NW; Kalra PA
BMC Nephrol; 2020 May; 21(1):202. PubMed ID: 32471368
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitors and chronic kidney disease risk: a comparative study with histamine-2 receptor antagonists.
Kweon T; Kim Y; Lee KJ; Seo WW; Seo SI; Shin WG; Shin DH
Sci Rep; 2023 Dec; 13(1):21169. PubMed ID: 38036592
[TBL] [Abstract][Full Text] [Related]
19. Kidney function decline associated with proton pump inhibitors: results from the ELSA-Brasil cohort.
Dos Santos AS; de Menezes ST; Silva IR; Oliveira WN; Pereira ML; Mill JG; Barreto SM; Figueiredo RC
BMC Nephrol; 2023 Sep; 24(1):285. PubMed ID: 37770872
[TBL] [Abstract][Full Text] [Related]
20. Demographic and health-related predictors of proton pump inhibitor (PPI) use and association with chronic kidney disease (CKD) stage in NHANES population.
Devraj R; Deshpande M
Res Social Adm Pharm; 2020 Jun; 16(6):776-782. PubMed ID: 31445985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
